Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Clin Cancer Res. 2021 Feb 16;27(9):2604–2612. doi: 10.1158/1078-0432.CCR-20-4772

Figure 4. Association between KRAS-mutation status and disease-free survival in The Cancer Genome Atlas cohort (N=476).

Figure 4.

Three-year disease-free survival for (A) all KRAS-mutant (KRASmut) tumors versus KRAS wild-type (KRASwt) tumors and for (B) KRASG12C tumors versus all other KRAS-mutant tumors (KRASother).